Home | Publications | Country | Asia / Pacific | India place holder
place holder place holder

India

Indian Pharmaceutical Market, 2006-2011


Publication Date   June 2006
Publisher   Visiongain
Product Type   Report
Pages   143
ISBN Number   not applicable
Product Code   VIS033
Ask a question about this product?

Price £1,499.00

approximately: $2,801 | €1,901

Summary


Please Note: Reports are sold based on the user licenses indicated. The reports will be accessible in Flash format via an online reading room on the publisher website, allowing viewing and printing capabilities only. Within one to two business days after placing the order,the client will receive an email with information on accessing their purchase.

The Indian pharmaceutical market is the 15th largest individual market by sales, but the 4th by volume of product; with domestic drug sales of almost $5 billion.For many years the Indian pharmaceutical market has been seen as a no go area for the R&D based MNCs. The market became dominated by copied generic drugs produced at low-cost by Indian companies.

One full year after the introduction of the WTO TRIPS and in the midst of the practical implications of ensuring compliance with product patents, how is the Indian pharmaceutical industry facing up to new regulations to its market?

The Indian pharmaceutical market is entering a pivotal period of change. Although it is unlikely to see significant growth before 2011, extensive company activity is expected to face international competitiveness. Global pharmaceutical companies have already begun to take advantage of the changing regulatory and economic conditions in India. The following five years will see further merger and acquisition activity, including key overseas acquisitions.

Why you should buy this report

Significant change is imminent within and from the Indian pharmaceutical market. Global MNCs cannot afford to ignore the cost advantages that the Indian market offers.
Key companies are examined, recent histories summarised and strategies outlined to provide indications of potential strengths.
The key IP changes resulting from the acceptance of the WTO TRIPS are outlined.
This report considers the latest financial and anecdotal information from the Indian pharmaceutical market to enable the most accurate assessment of the medium-term future potential of this $5 billion market.

The leading companies mentioned in this report

  • 1. Ranbaxy Laboratories
  • 2. Cipla
  • 3. Dr Reddy's Laboratories
  • 4. Sun Pharmaceuticals
  • 5. Nicholas Piramal
  • 6. Zydus Cadila
  • 7. Biocon
  • 8. Glenmark Pharmaceuticals
  • 9. Wockhardt Ltd
  • 10. Orchid Chemicals

Content


  • 1. Executive Summary
    • 1.1 The Indian Pharmaceutical Market Will Be Worth $7.58 Billion By 2011
    • 1.2 Aims, Scope and Format of the Report
    • 1.3 Research Methodology
  • 2. Introduction
  • 3. The Indian Healthcare System
    • 3.1 Organisation of the Indian Healthcare System
    • 3.2 Emphasis on Local Participation
    • 3.3 State Financed Research and Technology
    • 3.4 Clean Water and Sewage Disposal
    • 3.5 Finance and Resources
    • 3.6 Physical infrastructure
    • 3.7 Indian Healthcare Neglects the Poor
    • 3.8 The Indian Market for Healthcare
    • 3.9 Indian Healthcare Statistics
    • 3.10 India's Healthcare Market Has a High Potential
    • 3.11 The High Price of Being Ill in India
    • 3.12 The Disease Burden in India
    • 3.13 HIV Will Grow
    • 3.14 TB Is the Biggest cause of Death in India
    • 3.15 Maternal, Perinatal and Childhood Conditions Have the Highest Burden of Disease
    • 3.16 Malaria is Still Highly Prevalent in India
    • 3.17 Non-communicable Conditions and the Rise of Western Diseases in India
    • 3.18 Cardiovascular Disease is On the Rise
    • 3.19 Diabetes Will Increase
    • 3.20 Incidence of Cancer Will Increase
    • 3.21 Mental Health Disorders
    • 3.22 Asthma and COPD 3.23 Blindness Prevalence Will Remain Unchanged
    • 3.24 The Drug Price Control Order (DPCO)
    • 3.25 A List of the Key Pharmaceutical Organisations in India
  • 4. The Indian Economy
    • 4.1 IMF Forecasts Continuing Positive Economic Growth
    • 4.2 Life Expectancy is Still Low in India Compared to the West
    • 4.3 Technical Labour Force Remains Important
    • 4.4 Indian Agriculture Is Inefficient
    • 4.5 Indian Industry is Set for High Growth Levels
    • 4.6 The Services Sector Will Also Grow
    • 4.7 The Indian Rupee
    • 4.8 India's Growing Future
    • 4.9 Poverty Is Still High in India
    • 4.10 Steps Taken to Reduce Bureaucracy and Corruption
    • 4.11 Occupation and Unemployment
  • 5. Indian IP, WTO and TRIPS
    • 5.1 Anticipation of an Open Indian Market
    • 5.2 Indian Patent Act Allowed Only Process Patents
    • 5.3 TRIPS Agreement Changes Format of the Indian Pharma Market
    • 5.4 Intermediary Measures Should Smooth Transition
    • 5.5 The Mailbox System
    • 5.6 Does the Drug Price Control Order Help or Hinder?
    • 5.7 Predicted Consequences of India's New Pharmaceutical IP System
      • 5.7.1 Potential Advantages for the Indian Pharmaceutical Market
      • 5.7.2 Potential Disadvantages for the Indian Pharmaceutical Market
  • 6. The Indian Pharmaceutical Market
    • 6.1 The Indian Pharmaceutical Market Has Shown Historical Growth
    • 6.2 Generics Dominate Branded Products on the Indian Pharmaceutical Market
      • 6.2.1 Antibiotics Lead the Indian Market
      • 6.2.2 Volume Greater Driver than New Products
    • 6.3 India's OTC Market
    • 6.4 Infrastructure Weak - Distribution Vital
    • 6.5 Counterfeiting
    • 6.6 The Future of the Indian Pharmaceutical Market Looks Positive
    • 6.7 The Localised Nature of the Indian Pharmaceutical Market Will Alter
  • 7. The Impact of Indian Companies on the World Pharma Market
    • 7.1 Contract Manufacturing and R&D Activity
    • 7.2 API Sourcing
  • 8. Clinical Trials Industry
    • 8.1 A SWOT Analysis of Outsourcing Clinical Trials to India
    • 8.2 Many Factors are Considered When Deciding Clinical Trial Location but Quality of Data Should Be Paramount
    • 8.3 India as a Model for Rapid Growth in the Clinical Trials Industry
    • 8.4 Expanding Pharmaceutical Investment in India is Led by Clinical Trials
    • 8.5 Changes to the Law Have Caused Rapid Growth of Clinical Research
    • 8.6 Rapid Recruitment Is Driven by a Large Patient Population and an Organised Healthcare System
    • 8.7 Ethical Considerations in India
    • 8.8 What Is India Doing to Promote Clinical Research?
    • 8.9 Forecast: What Is the Future of Indian Clinical Research?
  • 9. SWOT Analysis of the Indian Pharmaceutical Market
  • 10. An Overview of the Leading Indian Pharmaceutical Companies
    • 10.1 Ranbaxy
      • 10.1.1 Ranbaxy Wins Lipitor Patent Decision in Austria
      • 10.1.2 R&D Investment Offers Another Strategy
      • 10.1.3 Ranbaxy's M&A Activity
      • 10.1.4 Ranbaxy Summary
    • 10.2 Cipla 10.2.1 Will Cipla Struggle to Adapt?
      • 10.2.2 Cipla Summary
    • 10.3 Dr Reddy's
      • 10.3.1 US Market Generic Competition Hits Dr Reddy's
      • 10.3.2 Dr Reddy's Active with M&A
      • 10.3.3 Dr Reddy's Pipeline
      • 10.3.4 Dr Reddy's Summary
    • 10.4 Other Leading Companies
      • 10.4.1 Nicholas Piramal Adopts Co-operative Strategy
      • 10.4.2 Wockhardt Achieves Notable Successes in US and UK
      • 10.4.3 Glenmark Pharmaceuticals- US Market Activity
      • 10.4.4 Orchid Develops From Alliance-based to Brand Market Presence
      • 10.4.5 Supporting Companies Seek Developing Strategies
    • 10.5 Conclusion
  • 11. Conclusion - Key Aspects of the Indian Pharmaceutical Industry
  • Tables
    • Table 3.1 Access to Safe Water and Sewage Disposal, 2005
    • Table 3.2 Indian Healthcare Expenditure Statistics, 2005
    • Table 3.3 Indian Health Facilities and Human Resources, 2004 Table 3.4 Indian Disease Burden, 1998
    • Table 4.1 Indian GDP Leveles, 2005
    • Table 4.2 Population, General Health and Economic Statistics, 2005
    • Table 6.1 The Top 20 Pharmaceutical Markets by Country, 2005
    • Table 6.2 The Leading Indian Pharmaceutical Companies, 2005
    • Table 6.3 Generic Market Share By Value and Volume, 2005
    • Table 6.4 Revenue ($m) and Growth Rate (%) of the Leading Drugs on the Indian Market,2005
    • Table 6.5 Sectors Contributing to the Overall Growth of the Indian Pharmaceutical Market, 1995-2002
    • Table 6.6 Forecast Revenue of the Indian Pharmaceutical Market, 2004-2011
    • Table 7.1 API and Formulation Production ($m) in India, 2003-2005
    • Table 7.2 API, Formulation and Intermediate Imports, ($m) 2003-2005
    • Table 7.3 API and Formulation Exports ($m), 2003-2005
    • Table 7.4 Comparable Cost Advantages (%) from India's Pharmaceutical Market, 2005
    • Table 7.5 Recent MNC Infrastructure Activity in the Indian Pharmaceutical Market, 2005
    • Table 8.1 SWOT Analysis of Outsourcing Clinical Trials to Developing Countries, 2006
    • Table 8.2 Estimated Cost($m) of Clinical Trials in the US and India, 2006
    • Table 8.3 Comparison of Disease Prevalence (m) in the US and India
    • Table 9.1 SWOT Anaylsis of the Indian Pharmaceutical Market, 2006
    • Table 10.1 The Leading Indian Pharmaceutical Companies
    • Table 10.2 Leading Companies in the Indian Pharma Market by Revenue ($m), 2005
    • Table 10.3 Leading Indian Pharmaceutical Companies by Total Revenue ($m), 2005
    • Table 10.4 Ranbaxy's Leading Products by Revenue, 2005
    • Table 10.5 Ranbaxy Revenue Generation by Region, 2005
    • Table 10.6 Pipeline Projects, Ranbaxy, 2006
    • Table 10.7 Cipla's Leading Products by Revenue, 2005
    • Table 10.8 Cipla Revenue Generation by Region, 2005
    • Table 10.9 Dr Reddy's Leading Products by Revenue, 2005
    • Table 10.10 Dr Reddy's Revenue Generation by Region, 2005
    • Table 10.11 Pipeline Projects, Dr Reddy's, 2006
  • Figures
    • Figure 1.1 Forecast Revenue ($m) of the Indian Pharmaceutical Market, 2004-2011
    • Figure 6.1 Indian Pharmaceutical Market Revenue ($bn), 2000-2005
    • Figure 6.2 Indian Drug Revenue ($m) By Therapeutic Class, 2005
    • Figure 6.3 Indian Drug Growth Rate (%) By Therapeutic Class, 2005
    • Figure 6.4 Forecast Revenue ($m) of the Indian Pharmaceutical Market, 2004-2011
    • Figure 8.1 Factors Affecting Clinical Trial Location
    • Figure 8.2 Clinical Trial Revenues ($m) in India, 2005-2010
    • Figure 8.3 Clinical Trial Growth Rates (%) in India, 2005-2010
    • Figure 10.1 Ranbaxy's Leading Products by Total Revenue Share (%), 2005
    • Figure 10.2 Ranbaxy Revenue Generation by Region, 2005
    • Figure 10.3 Cipla Leading Products by Total Revenue Share (%), 2005
    • Figure 10.4 Cipla Revenue Generation by Region, 2005
    • Figure 10.5 Dr Reddy's Leading Products by Total Revenue Share (%), 2005
    • Figure 10.6 Dr Reddy's Revenue Generation by Region, 2005
    • Figure 11.1 Forecast Revenue for the Indian Pharmaceutical Market, 2006-2011